{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:53:32Z","timestamp":1764053612927,"version":"3.45.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.euo.2019.06.010","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T01:12:23Z","timestamp":1562116343000},"page":"291-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men"],"prefix":"10.1016","volume":"3","author":[{"given":"Thenappan","family":"Chandrasekar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard G.","family":"Gomella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Hegarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Yau","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veda N.","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2019.06.010_bib0155","unstructured":"National Cancer Institute. Genetics of prostate cancer (PDQ\u00ae). https:\/\/www.cancer.gov\/types\/prostate\/hp\/prostate-genetics-pdq."},{"key":"10.1016\/j.euo.2019.06.010_bib0160","doi-asserted-by":"crossref","first-page":"e27130","DOI":"10.1371\/journal.pone.0027130","article-title":"An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis","volume":"6","author":"Kicinski","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2019.06.010_bib0165","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.seminoncol.2016.08.001","article-title":"Familial prostate cancer","volume":"43","author":"Giri","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.euo.2019.06.010_bib0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2017.74.1173","article-title":"Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017","volume":"36","author":"Giri","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2019.06.010_bib0175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2019.06.010_bib0180","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/gim.2013.193","article-title":"Prostate cancer incidence in males with Lynch syndrome","volume":"16","author":"Haraldsdottir","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.euo.2019.06.010_bib0185","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"journal-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): genetic\/familial high-risk assessment: Breast and ovarian (version 3.2019)","year":"2019","author":"NCCN","key":"10.1016\/j.euo.2019.06.010_bib0190"},{"journal-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): prostate (version 1.2019)","year":"2019","author":"NCCN","key":"10.1016\/j.euo.2019.06.010_bib0195"},{"key":"10.1016\/j.euo.2019.06.010_bib0200","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.6004\/jnccn.2014.0128","article-title":"Gene panel testing for inherited cancer risk","volume":"12","author":"Hall","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2019.06.010_bib0205","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility","volume":"33","author":"Robson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2019.06.010_bib0210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2019.06.010_bib0215","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2019.06.010_bib0220","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.bjc.6604453","article-title":"Rapid progression of prostate cancer in men with a BRCA2 mutation","volume":"99","author":"Narod","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2019.06.010_bib0225","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.010_bib0230","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.010_bib0235","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/cncr.29075","article-title":"Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the women's health initiative study","volume":"121","author":"Beebe-Dimmer","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2019.06.010_bib0240","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2006.05.5889","article-title":"Disparities in genetic testing: thinking outside the BRCA box","volume":"24","author":"Hall","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2019.06.010_bib0245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12889-017-4375-8","article-title":"Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review","volume":"17","author":"Hann","year":"2017","journal-title":"BMC Public Health"},{"key":"10.1016\/j.euo.2019.06.010_bib0250","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10897-013-9663-6","article-title":"African American women's limited knowledge and experiences with genetic counseling for hereditary breast cancer","volume":"23","author":"Sheppard","year":"2014","journal-title":"J Genet Couns"},{"key":"10.1016\/j.euo.2019.06.010_bib0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.6004\/jnccn.2017.0003","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: breast and ovarian, version 2.2017","volume":"15","author":"Daly","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2019.06.010_bib0260","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)35617-3","article-title":"Hereditary prostate cancer: epidemiologic and clinical features","volume":"150","author":"Carter","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2019.06.010_bib0265","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djh034","article-title":"Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability","volume":"96","author":"Umar","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2019.06.010_bib0270","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10897-011-9462-x","article-title":"Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the national society of genetic counselors","volume":"21","author":"Riley","year":"2012","journal-title":"J Genet Couns"},{"key":"10.1016\/j.euo.2019.06.010_bib0275","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"year":"2018","series-title":"Clovis oncology receives breakthrough therapy designation for Rubraca\u00ae (rucaparib) for treatment of BRCA1\/2-mutated metastatic castration resistant prostate cancer (mCRPC)","key":"10.1016\/j.euo.2019.06.010_bib0280"},{"key":"10.1016\/j.euo.2019.06.010_bib0285","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2019.06.010_bib0290","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.06.010_bib0295","first-page":"10.1200","article-title":"Evolving intersection between inherited cancer genetics and therapeutic clinical trials in prostate cancer: a white paper from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium","volume":"2018","author":"Carlo","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2019.06.010_bib0300","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/oxfordjournals.aje.a009259","article-title":"Comparison of self-reported and database-linked family history of cancer data in a case\u2013control study","volume":"146","author":"Kerber","year":"1997","journal-title":"Am J Epidemiol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931119300859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931119300859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:45:21Z","timestamp":1762875921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931119300859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2588931119300859"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2019.06.010","relation":{},"ISSN":["2588-9311"],"issn-type":[{"type":"print","value":"2588-9311"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2019.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}